Yale School of Medicine
New Haven, Connecticut, 06510, United States
NCT Number: NCT01249274
The investigators propose a placebo-controlled, randomized clinical trial that would enroll 50 postpartum women with a history of cocaine abuse or dependence to assess whether progesterone (100mgs twice daily) decreases postpartum cocaine use.
Looking for future studies?
Notify Me18 year–50 year
Female
Interventional
Not applicable
New Haven, Connecticut, 06510, United States
Specific Aim 1: To evaluate whether postpartum women with a history of cocaine abuse or dependence use less cocaine if they are randomized to progesterone than placebo.
Hypothesis 1: Compared to women who are randomized to placebo, those assigned to progesterone will use less cocaine as measured by urine toxicology results and self-reported days of use.
Specific aim 2: To obtain information about the safety and tolerability of progesterone treatment in the postpartum period.
Hypothesis 2: Side effects for progesterone will be similar to those of placebo.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Women will be ineligible for the trial if they:
100mgs progesterone twice daily
Other names: prometrium
Matched placebo pills to be taken twice daily
Time frame: Weekly measurements, Baseline to 12 weeks
Primary aim: to evaluate whether postpartum women with a history of cocaine abuse or dependence use less cocaine if they are randomized to progesterone than placebo. Measured by self-reported days of cocaine use per week via substance use calendar.
Time frame: baseline, end of trial (week 12), 3-month post-trial follow-up
Primary aim: to evaluate whether postpartum women with a history of cocaine abuse or dependence use less cocaine if they are randomized to progesterone than placebo. Measured by self-reported days of cocaine use per week during the trial period and during 3 month follow up using the substance use calendar
Time frame: weekly measurements, baseline to 12 weeks
Primary aim: to evaluate whether postpartum women with a history of cocaine abuse or dependence use less cocaine if they are randomized to progesterone than placebo. Urine tox tests obtained qualitative and quantitative data on cocaine metabolites and other substances.
Time frame: baseline, end of trial (week 12) and 3-month post-trial follow-up
Primary aim: to evaluate whether postpartum women with a history of cocaine abuse or dependence use less cocaine if they are randomized to progesterone than placebo. Urine tox tests obtained qualitative and quantitative data on cocaine metabolites and other substances.
Time frame: 12 weeks postpartum
To obtain information about the safety and tolerability of progesterone treatment in the postpartum period, women were queried at every visit about onset of adverse events, their seriousness, and their relatedness to study medication. Such data was monitored in SAETRS.
Time frame: baseline to 12 weeks
CCQ-Brief is a ten-item questionnaire developed from the 45-item CCQ. Each item is scored on a visual analogue scale ranging from 1-7, and items are averaged to yield a score from 1 to 7. Higher scores indicate stronger cocaine cravings.
Time frame: baseline to 12 weeks
EPDS scores were measured to detect depression as a possible adverse event and compare scores between the two groups. The scale consists of 10 items. Each item is scored from 0 to 3, and the 10 items are summed to calculate a total score with a possible range of 0 to 30 and higher scores indicating more severe depression.
Time frame: week 2, week 6, week 10, week 12
A comparison of salivary progesterone concentrations across all samples for all timepoints
Yale University
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05857852
Chemically-Induced Disorders, Cocaine Abuse
Charlottesville, Virginia, United States
View Trial DetailsNCT04907357
Chemically-Induced Disorders, Cocaine Abuse
Winston-Salem, North Carolina, United States
View Trial DetailsNCT02563769
Chemically-Induced Disorders, Cocaine Abuse
Philadelphia, Pennsylvania, United States
View Trial DetailsNCT00842517
Chemically-Induced Disorders, Cocaine Abuse
Philadelphia, Pennsylvania, United States
View Trial Details